modest guidanc like tap
plenti move piec head guidanc head cah
result mon aug bmo focu compani offici guidanc
variou compon particularli light recent brand drug inflat trend
headwind within medic busi recal compani alreadi indic
expect modest ep growth recent revis ep
guidanc specif detail relat
modest ep growth potenti lower expect brand price may
impact guidanc trim ep estim
impli growth ep estim conserv view
brand inflat factor may form view includ effort
return profit within cordi busi drug custom contract re-pric
expect occur next year continu gener deflat loss
pharmerica contract perhap largest headwind aforement
factor difficulti relat cordi recal compani work improv
profit busi see signific cost issu lead ep miss
ep guidanc reduct note cah overal tax rate also
heavili influenc profit cordi key
expect in-lin quarter trim ep quarter expect
compani post ep essenti in-lin street view
sale bln vs street bln view channel check larg
indic gener price remain soft quarter fewer new first time gener
launch howev ultim expect quarterli result overshadow
guidanc maintain ew rate price target base
ep
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight equal weight
compani continu see gener price deflat
issu within cordi busi point
larg price stock see rel
minim upsid downsid
upsid case gener price
improv modestli lead multipl expans
ep
downsid case see gener price continu
remain heavili deflationari improv
seen cordi busi lead price
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
 quarterli revenu model mil cahcahcahcahcahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin quarterli oper profit mil cahcahcahcahcahcahcahoper profit ebit ebit ebit ebit barclay
 quarterli incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
digit percentag growth vs pymid-singl digit percentag growth vs pymid-singl digit percentag growth vs pymid-singl digit percentag growth vs pymid-singl digit percentag growth vs pynon-gaap effect tax expens dilut eps-flat mid-singl digit ep excl china dilut key ep headwind discret tax law benefit discret itemsm a-rel intang exclud patient recoveri busi pharma segmentrevenu growth-low mid singl digit growth-low mid singl digit growth-low mid singl digit growth-low mid singl digit growth-low mid singl digit growthprofit ebit growthful year ebit high singl digits-down low doubl digits-down low doubl digits-down low doubl digits-down low doubl digits-down high singl low doubl digitsgener pricing-mid-singl digit deflat sell-sid -mid-singl digit deflat sell-sid -mid-singl digit deflat sell-sid -mid-singl digit deflat sell-sid mid-to-high -singl digit deflat sell-sid brand inflat full fiscal inflat full fiscal inflat full fiscal inflat full fiscal inflat full fiscal yeari/t investments-increment expens increas y-o-y-increment expens increas y-o-y-increment expens increas y-o-y-increment expens increas y-o-y-increment expens increas y-o-ygener launch contribution-new launch benefit much lower y-o-y-new launch benefit much lower y-o-y-new launch benefit much lower y-o-y-new launch benefit much lower y-o-y-new launch benefit much lower y-o-yr oak contribution-less benefit y-o-y-less benefit y-o-y-less benefit y-o-y-less benefit y-o-yflat y/yspecialti contribution-double-digit revenue ebit growth-double-digit revenue ebit growth-double-digit revenue ebit growth-double-digit revenue ebit growth-double-digit revenue ebit growth china sale close guid assum full-yr contributionep guid assum full-yr contributionep guid assum full-yr contribution-ep lower earli sale close-ep lower earli sale closemed segmentrev growthhigh-teen revenue growthhigh-teen revenue growthhigh-teen revenue growthhigh-teen revenue growthhigh-teen revenue growthebit growthstrong double-digit growth w/ strong double-digit ebit growthstrong double-digit ebit growthstrong double-digit ebit growthstrong double-digit ebit growth patient recoveri accret inventori step-up inventori step-up inventori step-up inventori step-up inventori step-up medic busi ex deal solid growth core medic ex- solid growth core medic ex- solid growth core medic ex- -flat-to-down due cordis/glovesprofit high teensebit ebit margin exce ebit margin exce ebit margin exce ebit margin exce reach affair va med contractsignificantli y-o-i start y-o-i start y-o-i start y-o-i start y-o-i start devic tax notesno reinstat medic devic taxno reinstat medic devic taxno reinstat medic devic taxno reinstat medic devic taxno reinstat medic devic tax barclay cardin
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
